reports
Anika Reports Third Quarter 2025 Financial Results
Anika Reports Third Quarter 2025 Financial Results Commercial Channel revenue up 22% with continued strong Integrity™ Implant System and Hyalofast® growth, and double-digit International OA Pain Management growth Third and final Hyalofast PMA module filed and data released Cingal® achieved commercial milestone of more than one million injections worldwide since 2016 Reaffirming Fiscal 2025 guidance and long-term outlook and commencing a $15 million 10b5-1 share repurchase BEDFORD, Mass., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (Nasdaq: ANIK), a global leader in the ...
Anika Therapeutics Reports Filing of Final PMA Module for Hyalofast® C...
Anika Therapeutics Reports Filing of Final PMA Module for Hyalofast® Cartilage Repair Scaffold and Data from U.S. Pivotal FastTRACK Phase III Study BEDFORD, Mass., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global leader in joint preservation and regenerative solutions, announced that it filed the third and final module of its Premarket Approval application (PMA) for Hyalofast—its resorbable, hyaluronic acid-based scaffold used with autologous bone marrow aspirate concentrate (BMAC) for treating articular cartilage defects in the knee. The Company also re...
Anika to Issue Third Quarter 2025 Financial Results on Wednesday, Nove...
Anika to Issue Third Quarter 2025 Financial Results on Wednesday, November 5, 2025 BEDFORD, Mass., Oct. 23, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, announced today that it will issue its third quarter 2025 financial results before the opening of the market on Wednesday, November 5, 2025, followed by a conference call at 8:30 a.m. ET to discuss its results and business highlights. The conference call can be accessed by dialing 1-800-717-1738 (toll-free domestic) or 1-646-307-1865 (international) and providing the con...
Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) BEDFORD, Mass., Sept. 05, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: ANIK), a global leader in the osteoarthritis pain management and regenerative solutions spaces focused on early intervention orthopedics, today announced that on September 2, 2025, Anika granted non-statutory stock options (“Options”) covering an aggregate of 2,500 shares of common stock at a per share exercise price of $9.15, which equaled the closing price of common stock on the Nasdaq Global Select Market on the grant date, to one newly hired non-executive e...
Boeing Co: 1 director
A director at Boeing Co maiden bought 2,200 shares at 226.100USD and the significance rating of the trade was 93/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clea...
Anika Reports Second Quarter 2025 Financial Results
Anika Reports Second Quarter 2025 Financial Results Regenerative Solutions revenue up 41% with Integrity™ Implant System ahead of expectations and continued strong Hyalofast® growth; Integrity surpasses full year 2024 performance and is on pace to more than double in 2025 Company released topline results for Hyalofast® clinical trial which did not meet pre-specified co-primary end points; Hyalofast demonstrated statistically significant improvements in pre-defined secondary endpoints and other measures; Company plans to file the final PMA module in second half 2025 Reaffirming Fis...
Anika Reports Topline Results from U.S. Pivotal FastTRACK Phase III St...
Anika Reports Topline Results from U.S. Pivotal FastTRACK Phase III Study for Hyalofast® Cartilage Repair Scaffold and Provides Program Update Hyalofast consistently demonstrated improvements over microfracture, but missed on statistical significance of the pre-specified co-primary endpoints of percent change in KOOS Pain and IKDC function Hyalofast showed statistically significant improvements over microfracture in pre-defined secondary endpoints and other measures that align with prior FDA approvals for cartilage repair products Hyalofast has been used to treat over 35,000 pati...
Anika to Issue Second Quarter 2025 Financial Results on Wednesday, Jul...
Anika to Issue Second Quarter 2025 Financial Results on Wednesday, July 30, 2025 BEDFORD, Mass., July 16, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, announced today that it will issue its second quarter 2025 financial results before the opening of the market on Wednesday, July 30, 2025, followed by a conference call at 8:30 a.m. ET to discuss its results and business highlights. The conference call can be accessed by dialing 1-800-717-1738 (toll-free domestic) or 1-646-307-1865 (international) and providing the confere...
Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) BEDFORD, Mass., July 03, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: ANIK), a global leader in the osteoarthritis pain management and regenerative solutions spaces focused on early intervention orthopedics, today announced that on July 1, 2025, Anika granted non-statutory stock options (“Options”) covering an aggregate of 2,500 shares of common stock at a per share exercise price of $10.53, which equaled the closing price of common stock on the Nasdaq Global Select Market (“Closing Price”) on the grant date, to one newly hired no...
Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) BEDFORD, Mass., June 05, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: ANIK), a global leader in the osteoarthritis pain management and regenerative solutions spaces focused on early intervention orthopedics, today announced that on June 2, 2025, Anika granted non-statutory stock options (“Options”) covering an aggregate of 2,500 shares of common stock at a per share exercise price of $11.45, which equaled the closing price of common stock on the Nasdaq Global Select Market (“Closing Price”) on the grant date, to one newly hired no...
Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) BEDFORD, Mass., May 12, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: ANIK), a global leader in the osteoarthritis (“OA”) pain management and regenerative solutions spaces focused on early intervention orthopedics, today announced that on May 1, 2025, Anika granted non-statutory stock options (“Options”) covering an aggregate of 5,000 shares of common stock at a per share exercise price of $14.46, which equaled the closing price of common stock on the Nasdaq Global Select Market (“Closing Price”) on the grant date, to two newly hir...
Anika Reports First Quarter 2025 Financial Results
Anika Reports First Quarter 2025 Financial Results First Quarter 2025 Commercial Channel revenue up 18% Integrity™ Implant System continues sequential growth and is on pace to more than double procedures in 2025 Key regulatory and clinical milestones achieved for Hyalofast®, Cingal®, and Integrity Updating Fiscal 2025 OEM Channel revenue guidance and Adjusted EBITDA guidance BEDFORD, Mass., May 09, 2025 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (Nasdaq: ANIK), a global leader in the osteoarthritis (“OA”) pain management and regenerative solutions spaces focused on early interventio...
Anika to Participate in the Sidoti Virtual Investor Conference
Anika to Participate in the Sidoti Virtual Investor Conference BEDFORD, Mass., May 07, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: ANIK), a global leader in the osteoarthritis (“OA”) pain management and regenerative solutions spaces focused on early intervention orthopedics, today announced that management will participate in the Sidoti Virtual Investor Conference on Wednesday, May 21, 2025. Anika will host a virtual presentation with Q&A starting at 1:00pm ET. Webcast of the presentation and Q&A will be available in the section of Anika’s website, . An archive of the presentation will also be a...
Anika to Issue First Quarter 2025 Financial Results on Friday, May 9, ...
Anika to Issue First Quarter 2025 Financial Results on Friday, May 9, 2025 BEDFORD, Mass., April 25, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, announced today that it will issue its first quarter 2025 financial results before the opening of the market on Friday, May 9, 2025, followed by a conference call at 8:30 a.m. ET to discuss its results and business highlights. The conference call can be accessed by dialing 1-800-717-1738 (toll-free domestic) or 1-646-307-1865 (international) and providing the conference ID numb...
Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Anika Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) BEDFORD, Mass., April 07, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: ANIK), a global leader in the Osteoarthritis (“OA”) Pain Management and Regenerative Solutions space focused on early intervention orthopedics, today announced that on April 1, 2025, Anika granted non-statutory stock options (“Options”) covering an aggregate of 3,800 shares of common stock at a per share exercise price of $15.03, which equaled the closing price of common stock on the Nasdaq Global Select Market (“Closing Price”) on the grant date, to one newly ...
Anika Reports Fourth Quarter and Full Year 2024 Financial Results
Anika Reports Fourth Quarter and Full Year 2024 Financial Results Full Year 2024 results in line with guidance with Commercial Channel revenue up 17% Strong International OA Pain Management and greater than 40% sequential growth of Integrity™ Implant System drive Commercial Channel growth and 2024 results Key Regulatory and Clinical milestones achieved for Hyalofast®, Cingal®, and Integrity Strategic Sale of Parcus Medical complete; resources refocused on programs positioned to generate significantly higher returns BEDFORD, Mass., March 12, 2025 (GLOBE NEWSWIRE) -- Ani...
Anika Completes Divestiture of Parcus Medical
Anika Completes Divestiture of Parcus Medical Execution of Previously Announced Plan Sharpens Focus on Hyaluronic Acid-Driven OA Pain Management and High Growth Regenerative Solutions Portfolio BEDFORD, Mass., March 07, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: ANIK), a global leader in the Osteoarthritis Pain Management and Regenerative Solutions space focused on early intervention orthopedics, today announced the completion of the previously announced planned divestiture of its Parcus Medical business. Management Commentary“The sale of Parcus marks a critical step forward as we achieve the ...
- Dave Nicoski
- Ross LaDuke
PMT PENNYMAC MORTGAGE INVESTMENT TRUST
BKD BROOKDALE SENIOR LIVING INC.
WBA WALGREENS BOOTS ALLIANCE INC
PLOW DOUGLAS DYNAMICS INC.
NSP INSPERITY INC.
NEU NEWMARKET CORPORATION
MDLZ MONDELEZ INTERNATIONAL INC. CLASS A
INTC INTEL CORPORATION
HSY HERSHEY COMPANY
DLTR DOLLAR TREE INC.
BMRN BIOMARIN PHARMACEUTICAL INC.
BAX BAXTER INTERNATIONAL INC.
SBL SAFE BULKERS INC.
CYH COMMUNITY HEALTH SYSTEMS INC.
LKO LAKES OIL N.L.
AWK AMERICAN WATER WORKS COMPANY INC.
CWT CALIFORNIA WATER SERVICE GROUP
TNC TENNANT COMPANY
NGVT INGEVITY CORPORATION
KALV KALVISTA PHARMACEUTICALS
SSTI SHOTSPOTTER
VIAC VIACOMCBS INC. CLASS B
STTK SHATTUCK LABS
CSTM CONSTELLIUM SE CLASS A
LUNG PULMONX
BBWI BATH & BODY WORKS INC
UWMC UWM HLDGS CORP
UDMY UDEMY INC
AMGN AMGEN INC
NYMT NEW YORK MORTGAGE TRUST INC.
HSHP HIMALAYA SHIPPING LTD.
PCH PICOMAT PLASTIC JSC
Anika to Issue Fourth Quarter and Year-End 2024 Financial Results on W...
Anika to Issue Fourth Quarter and Year-End 2024 Financial Results on Wednesday, March 12, 2025 BEDFORD, Mass., Feb. 26, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: ANIK), a global joint preservation company in early intervention orthopedics, announced today that it will issue its fourth quarter and year-end 2024 financial results after the close of the market on Wednesday, March 12, 2025 and hold its investor conference call on the same day, at 5:00 p.m. ET to discuss its financial results and business highlights. The conference call can be accessed by dialing 1-800-717-1738 (toll-free domestic) ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.